• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[在使用维奈托克和阿扎胞苷诱导治疗急性髓性白血病期间多育赛多孢菌感染的发生情况]

[Development of Lomentospora prolificans infection during induction therapy with venetoclax and azacitidine for acute myeloid leukemia].

作者信息

Takahashi Wakana, Hatada Tatsuya, Saito Chizuru, Murata Ryoichi, Ueda Mikio, Miyamoto Toshihiro

机构信息

Department of internal medicine, Keiju Kanazawa Hospital.

Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University.

出版信息

Rinsho Ketsueki. 2024;65(8):742-746. doi: 10.11406/rinketsu.65.742.

DOI:10.11406/rinketsu.65.742
PMID:39231702
Abstract

Lomentospora prolificans is a rare filamentous fungus that causes invasive fungal disease (IFD) in immunocompromised patients with hematological malignancies, as well as hematopoietic cell or solid organ transplant recipients. A 75-year-old woman was diagnosed with acute myeloid leukemia, and started induction therapy with azacitidine and adjusted-dose venetoclax along with antifungal prophylaxis with fluconazole. On day 7, she became febrile and chest CT imaging showed multiple nodules in both lung fields, and the serum galactomannan antigen index became positive, indicating probable IFD. Anti-fungal therapy with liposomal amphotericin B was immediately initiated; however, the patient's condition rapidly deteriorated, and she died on day 15. L. prolificans was later identified in blood culture tests that had been repeatedly performed while she had been febrile. L. prolificans is generally resistant to most antifungal agents, which can make it fatal. As early definitive diagnosis is difficult, it may be appropriate to consider combination therapy when conventional anti-IFD therapy seems inadequate.

摘要

多育裂褶菌是一种罕见的丝状真菌,可在患有血液系统恶性肿瘤的免疫功能低下患者以及造血细胞或实体器官移植受者中引起侵袭性真菌病(IFD)。一名75岁女性被诊断为急性髓系白血病,并开始使用阿扎胞苷和调整剂量的维奈克拉进行诱导治疗,同时使用氟康唑进行抗真菌预防。第7天,她出现发热,胸部CT成像显示双肺野有多个结节,血清半乳甘露聚糖抗原指数呈阳性,提示可能患有IFD。立即开始使用脂质体两性霉素B进行抗真菌治疗;然而,患者病情迅速恶化,于第15天死亡。后来在她发热期间反复进行的血培养检测中发现了多育裂褶菌。多育裂褶菌通常对大多数抗真菌药物耐药,这可能使其具有致命性。由于早期明确诊断困难,当传统的抗IFD治疗似乎不足时,考虑联合治疗可能是合适的。

相似文献

1
[Development of Lomentospora prolificans infection during induction therapy with venetoclax and azacitidine for acute myeloid leukemia].[在使用维奈托克和阿扎胞苷诱导治疗急性髓性白血病期间多育赛多孢菌感染的发生情况]
Rinsho Ketsueki. 2024;65(8):742-746. doi: 10.11406/rinketsu.65.742.
2
Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia.联合唑类抗真菌药物与维奈托克联合阿扎胞苷治疗新诊断的急性髓系白血病患者。
Hematology. 2024 Dec;29(1):2433172. doi: 10.1080/16078454.2024.2433172. Epub 2024 Nov 25.
3
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.新诊断的急性髓系白血病患者接受维奈托克联合阿扎胞苷治疗时是否进行抗真菌预防与真菌感染频率的关系。
Br J Haematol. 2024 Nov;205(5):1746-1750. doi: 10.1111/bjh.19670. Epub 2024 Jul 23.
4
Disseminated Infection by Scedosporium/Lomentospora during Induction Therapy for Acute Myeloid Leukemia Complicated by Nontuberculous Mycobacteria.播散性感染由 Scedosporium/Lomentospora 在急性髓细胞白血病并发非结核分枝杆菌诱导治疗期间。
Intern Med. 2024 May 15;63(10):1465-1471. doi: 10.2169/internalmedicine.2159-23. Epub 2023 Oct 13.
5
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中,venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效:一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
6
Strategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.
J Infect Chemother. 2025 Feb;31(2):102576. doi: 10.1016/j.jiac.2024.12.005. Epub 2024 Dec 4.
7
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.维奈克拉联合阿扎胞苷治疗日本急性髓系白血病患者的 1 期临床试验结果。
Jpn J Clin Oncol. 2021 May 28;51(6):857-864. doi: 10.1093/jjco/hyab018.
8
Phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in older patients with newly diagnosed acute myeloid leukemia.西达本胺联合CAG及维奈克拉-阿扎胞苷治疗新诊断老年急性髓系白血病的2期研究
Front Immunol. 2025 Feb 26;16:1525110. doi: 10.3389/fimmu.2025.1525110. eCollection 2025.
9
Increased trough concentration of venetoclax when combined with itraconazole for acute myeloid leukemia.伏立康唑联合 venetoclax 用于治疗急性髓系白血病时,伏立康唑的谷浓度增加。
Ann Hematol. 2024 Nov;103(11):4497-4502. doi: 10.1007/s00277-024-05845-2. Epub 2024 Sep 27.
10
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.